low - Revenue is 75%+ government contracts with multi-year visibility, insulating from GDP fluctuations. Naval nuclear work is driven by 30-year shipbuilding plans and geopolitical priorities rather than economic cycles. Commercial nuclear fuel demand is tied to baseload electricity generation, which is relatively stable. Medical isotope demand is non-cyclical, driven by cancer treatment protocols.

Rising rates have modest negative impact on valuation multiples given defensive growth profile, but minimal operational impact. BWXT carries moderate debt ($1.5B net debt, 1.2x D/E) with manageable interest expense. Higher rates could pressure commercial nuclear utilities' capital spending on refueling, but impact is limited given contractual commitments. Government contract pricing is not directly rate-sensitive, though higher discount rates compress NPV of long-duration contracts.

growth - Attracts quality growth investors seeking defense exposure with 8-12% revenue CAGR driven by naval modernization supercycle, nuclear renaissance tailwinds, and medical isotope expansion. Premium valuation (38x EV/EBITDA, 15x P/B) reflects scarcity value of naval nuclear monopoly and visible multi-decade growth runway. Also appeals to ESG-focused investors viewing nuclear as clean energy solution. Recent 91% one-year return suggests momentum factor attraction.